(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)
* Merck rises on positive COVID-19 pill data
* Strong consumer, factory data boost economic hopes
* Indexes up: Dow 1.37%, S&P 1.07%, Nasdaq 0.56% (Updates to afternoon, adds dateline, changes byline)
Oct 1 (Reuters) – Wall Street advanced in a broad rally on Friday, after sorting out conflicting news about the economy, the battle against COVID, and legislative wrangling in Washington at the start of the fourth quarter.
All three major U.S. stock indexes began trending higher by late afternoon, buoyed by economically sensitive cyclicals.
“It’s the first day of trading in a new quarter so it’s common to see stocks move in and out of the plus and minus columns,” said Peter Cardillo, chief market economist at Spartan Capital Securities in New York. “September played its traditional role by cooling down the market and probably presenting a buying opportunity.”
Merck & Co Inc revealed that a recent study showed its experimental oral drug for COVID-19 cut risk of death and hospitalization by about 50%, sending its shares jumping about 10% and boosting economic reopening sentiment.
The news provided “another reason to be optimistic,” said Cardillo. “It lessens the threat of the virus and obviously that means more people going back to work, more spending.”
While U.S. President Joe Biden signed into law a stop-gap bill to continue the government through Dec. 3, lawmakers only succeeded in kicking the can down the road.
This lack of resolution helped prompt rating agency Fitch to issue a warning that the United States’ ‘AAA’ credit rating could be at risk.
A host of economic data released on Friday showed increased consumer spending and accelerated factory activity and elevated inflation growth, a formula that could help nudge the U.S. Federal Reserve toward shortening its timeline for tightening its accommodative monetary policy.